On Thursday, Shares of Southern Co (NYSE:SO), gained 1.68% to $42.89.
Southern Co, declared the launch of a new solar sales and installation service for customers startning July 1. As an unregulated offering, the program will be administered by Georgia Power Energy Services, a business unit more than 20 years old focused on providing turnkey installation of energy efficiency products for customers.
“Georgia has one of the fastest growing and most competitive solar markets in the country,” said Norrie McKenzie, vice president of renewable development for Georgia Power. “Our new solar offering further delivers on our commitment to provide the energy choices our customers want and the world class service they expect.”
The Southern Company, together with its auxiliaries, operates as a public electric utility company. It is involved in the generation, transmission, and distribution of electricity through coal, nuclear, oil and gas, and hydro resources in the states of Alabama, Georgia, Florida, and Mississippi.
Shares of AstraZeneca plc (ADR) (NYSE:AZN), inclined 1.31% to $65.49, during its last trading session.
AstraZeneca, presented at the European League Against Rheumatism Annual Congress (EULAR 2015) in Rome, results of its Phase III double-blind, multicenter, placebo-controlled trial CRYSTAL, investigating the potential of lesinurad, a selective uric acid re-absorption inhibitor (SURI), when used in combination with the xanthine oxidase inhibitor (XOI) febuxostat. The results demonstrated that lesinurad in combination with febuxostat lowered serum uric acid (sUA) levels and reduced tophus area to a greater extent than febuxostat alone. Lesinurad is an investigational agent that inhibits the uric acid transporter URAT1 in the kidney, increasing uric acid excretion and thereby lowering sUA. Lesinurad works in combination with febuxostat to provide a dual mechanism of action which enhances excretion and decreases production of uric acid.
The CRYSTAL study evaluated lesinurad (200mg or 400mg) in combination with febuxostat 80mg in patients who had at least one measurable tophus (deposits of uric acid crystals in joints and skin). Patients were administered febuxostat 80 mg orally once daily for 3 weeks before randomisation to the combination treatments.
AstraZeneca PLC engages in the discovery, development, and commercialization of prescription medicines for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection, and neuroscience diseases worldwide. Its principal products comprise Crestor for the treatment of dyslipidaemia and hypercholesterolemia; Seloken/Toprol-XL to control hypertension, and heart failure and angina; Onglyza for diabetes mellitus; Iressa for non-small cell lung cancer; Faslodex for breast cancer in post-menopausal women; and Zoladex for prostate cancer, breast cancer, and certain benign gynaecological disorders.
Finally, New Oriental Education & Tech Grp (ADR) (NYSE:EDU), ended its last trade with -0.25% loss, and closed at $ 23.80.
New Oriental Education & Tech Grp, declared that it will report its financial results for the fourth quarter and fiscal year 2015 ended May 31, 2015, before the U.S. market opens on July 21, 2015. New Oriental’s administration will host an earnings conference call at 8 AM on July 21, 2015, U.S. Eastern Time (8 PM on July 21, 2015, Beijing/Hong Kong Time).
New Oriental Education & Technology Group Inc. provides private educational services primarily in the People’s Republic of China. It offers test preparation courses to students taking language and entrance exams used by educational institutions in the United States, the Peoples Republic of China, and Commonwealth countries; and after-school tutoring courses for middle school and high school students to assist students enhance scores on entrance exams for admission into high schools or higher education institutions.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
